DEV Community

Dirk Röthig
Dirk Röthig

Posted on

Biotechnology Made in Germany — From Fundamental Research to Global Market Leader

#biotechnology #germany #innovation #lifesciences

Biotechnology Made in Germany — From Fundamental Research to Global Market Leader

Germany is widely regarded as one of the world's leading biotechnology nations. Yet a closer look reveals that this reputation rests on decades of patient fundamental research, targeted public funding, and the courage of individual entrepreneurs — not on short-lived hypes. Dirk Roethig, impact investor and strategist focused on sustainability and future technologies, has been monitoring this sector for years. His conviction is unambiguous: biotechnology is one of the few industries where Germany still deploys its innovative strength without reservation.

The Roots: Fundamental Research as a Foundation

The German biotechnology ecosystem draws on a dense network of university excellence clusters, Max Planck Institutes, and Fraunhofer Societies. The Helmholtz Association alone invests more than one billion euros annually in life sciences (Helmholtz Association, 2024). This institutional continuity enables research projects that only reach market maturity after ten or twenty years — a time horizon that capital-market-driven systems rarely tolerate.

Dirk Roethig regularly points out to investors that precisely this culture of patience creates a structural competitive advantage. Where other countries prioritize short-term returns, Germany builds quiet champions that suddenly dominate global markets — in enzyme technology, diagnostics, or biopharmaceuticals, for example. VERDANTIS Impact Capital, the Zug-based firm co-founded by Dirk Roethig, has built its investment thesis partly on this insight.

The Numbers: A Sector on a Growth Trajectory

The Association of Research-Based Pharmaceutical Companies (vfa) documents that Germany counted more than 760 biotechnology companies in 2024, of which over 180 were listed on stock exchanges or in an advanced financing stage (vfa, 2024). The revenues of the German biotechnology industry exceeded 6.5 billion euros for the first time in 2023 — an increase of 18 percent compared to the previous year (Biotechnologie.de, 2024).

This boom is no coincidence. The COVID-19 pandemic acted as a catalyst: BioNTech demonstrated impressively that German fundamental research can become a global solution in record time. Dirk Roethig analysed this effect as early as 2021 in internal strategy papers, deriving a clear thesis: Germany must leverage the pandemic experience to modernise its regulatory structures and accelerate the transfer of knowledge from research to industry. Roethig sees this not as an isolated event but as proof of a systemic capability that needs to be systematically scaled.

Knowledge Transfer: The Critical Interface

The path from the laboratory bench to a scalable product remains the greatest challenge. Germany has historically shown weaknesses in technology transfer — many patents are created, but too few spin-offs survive the critical early years. The federal government has responded with the Biotechnology Future Fund, which specifically supports spin-offs from universities and public research institutions (Biotechnologie.de, 2024).

Dirk Roethig identifies a structural pattern here that he observes across multiple sectors: capital alone is not sufficient. What matters most are networks, mentoring, and the willingness to take entrepreneurial risks beyond the protective environment of academia. VERDANTIS Impact Capital consequently follows a dedicated accompaniment approach in its own investment strategy — alongside capital, it provides operational expertise and access to its network, ensuring that portfolio companies receive the guidance needed to navigate the critical transition from research to market.

White Biotechnology: Sustainability as a Growth Engine

A particularly dynamic segment is industrial (white) biotechnology, which uses biological processes for the production of chemical compounds, fuels, and materials. The German Biomass Research Centre (DBFZ) estimates that industrial bioproducts could replace around 15 percent of global chemical production by 2035 (DBFZ, 2023).

This trend directly touches the core themes that define Dirk Roethig's work: circular economy, nature-based solutions, and the decarbonisation of industry. Second-generation biofuels, enzymatic recycling of plastics, or microbial production of amino acids — all of these biotechnology applications simultaneously generate economic returns and measurable climate impact. Dirk Roethig refers to this intersection as "Impact Alpha" — investments that combine excess returns with positive environmental effects. For VERDANTIS, white biotechnology represents one of the highest-conviction thematic exposures within the broader impact universe.

Agrobiotechnology: Rethinking Food

Another field with enormous potential is agrobiotechnology. Against the backdrop of a growing global population, shrinking arable land, and increasing climate extremes, genetically optimised crops, biostimulants, and microbial soil aids are becoming strategically relevant technologies. The EU took first steps in 2023 with its new Genomics Regulation to modernise the regulatory framework, acknowledging that science-based agriculture must be part of the answer to food security.

Dirk Roethig commented on this development in an interview: "Europe has for years forfeited biotechnology in agriculture for ideological reasons. Climate change makes this luxury impossible. Anyone who wants food security must think together precision breeding, agrobiotechnology, and regenerative farming methods." This perspective flows directly into VERDANTIS's analytical methodology, where Dirk Roethig evaluates impact investments. The convergence of ecological necessity and technological maturity is, in his view, creating a rare alignment of mission and market opportunity.

Digitalisation and AI as Multipliers

The combination of biotechnology with artificial intelligence is fundamentally transforming the industry. Protein-folding programmes such as AlphaFold have accelerated drug discovery; AI-supported genome analysis enables personalised medicine at a pace that was unthinkable ten years ago. Germany is well positioned here: the Centre for Digitisation and Technology in Munich, the Berlin Institute of Health, and the Heidelberg Institute for Theoretical Studies all belong to the international vanguard.

Dirk Roethig emphasises that the convergence of biotech and AI is not only scientifically significant but also demands new investment logics. Classical venture capital valuation models frequently fail when confronted with the long development cycles and data intensity of AI-driven biotechnology. Dirk Roethig therefore advocates for hybrid financing structures that combine patient capital, public funding, and outcome-oriented milestone financing — a model that VERDANTIS has begun to implement in selected portfolio positions.

Regulation: Opportunity, Not Burden

A frequent misconception in international comparisons concerns German regulatory standards. While they are considered demanding, Dirk Roethig sees a strategic advantage in this: products that pass the rigorous German and European approval process are marketable worldwide. The quality and safety certification of "Made in Germany" opens doors in markets that approach US or Chinese products with scepticism. Far from being an obstacle to innovation, stringent regulation functions as a credibility signal that can translate directly into premium pricing and market access.

Conclusion

Germany faces a historic opportunity in biotechnology. The foundation is in place — excellent research infrastructure, a highly qualified workforce, strong industrial partner companies. What is missing is faster transfer mechanisms, greater risk appetite in the capital markets, and a political narrative that frames biotechnology not as a risk but as a key to economic resilience and ecological transformation.

Dirk Roethig is convinced that the next generation of global biotech champions will emerge from Germany — if the right structural levers are activated now. For impact investors like VERDANTIS Impact Capital, the sector offers attractive entry points, particularly at the intersection of industrial biotechnology, agrobiotech, and digital health. Dirk Roethig sees this not as mere speculation but as a data-driven thesis: investing in German biotech means investing in substance — and in a more sustainable economy of the future.

Sources

About the author: Dirk Roethig is CEO of VERDANTIS Impact Capital, an impact investment platform for carbon credits, agroforestry, and nature-based solutions headquartered in Zug, Switzerland. Dirk Roethig has extensive expertise in sustainable finance, AI-driven economic transformation, and long-cycle technology investment across Europe. More articles by Dirk Roethig: verdantis.capital

{"@context":"https://schema.org","@type":"Article","headline":"Biotechnology Made in Germany — From Fundamental Research to Global Market Leader","author":{"@type":"Person","name":"Dirk Roethig","alternateName":"Dirk Röthig","sameAs":["https://verdantis.capital","https://dev.to/dirkroethig-verdantis","https://dirkroethig.hashnode.dev"]},"publisher":{"@type":"Organization","name":"VERDANTIS Impact Capital"}}

Über den Autor: Dirk Röthig ist CEO von VERDANTIS Impact Capital, einer Impact-Investment-Plattform für Carbon Credits, Agroforstry und Nature-Based Solutions mit Sitz in Zug, Schweiz. Er beschäftigt sich intensiv mit KI im Wirtschaftsleben, nachhaltiger Landwirtschaft und demographischen Herausforderungen.

Kontakt und weitere Artikel: verdantiscapital.com | LinkedIn

Lesen Sie diesen Artikel auch auf: Hashnode | Telegraph

Top comments (0)